Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47


EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB.

Clin Cancer Res. 2018 Dec 15;24(24):6548-6555. doi: 10.1158/1078-0432.CCR-18-1541. Epub 2018 Aug 28.


Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.

Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM.

J Thorac Oncol. 2018 Jul;13(7):1037-1042. doi: 10.1016/j.jtho.2018.03.031. Epub 2018 Apr 6.


Tumor biomarker testing in non-small-cell lung cancer: A decade of change.

VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, McDonald DC, Huberman MS, Kobayashi SS, Costa DB.

Lung Cancer. 2018 Feb;116:90-95. doi: 10.1016/j.lungcan.2018.01.002. Epub 2018 Jan 4.


Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB.

J Thorac Oncol. 2017 Nov;12(11):e175-e177. doi: 10.1016/j.jtho.2017.06.002. Epub 2017 Jun 10. No abstract available.


Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB.

Lung Cancer. 2017 Apr;106:17-21. doi: 10.1016/j.lungcan.2017.01.011. Epub 2017 Jan 25.


Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

Rangachari D, Drake L, Huberman MS, McDonald DC, VanderLaan PA, Folch E, Costa DB.

Cancer Treat Commun. 2016;9:41-43. doi: 10.1016/j.ctarc.2016.07.001. Epub 2016 Jul 5.


Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.

Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB.

J Thorac Oncol. 2017 May;12(5):878-883. doi: 10.1016/j.jtho.2016.12.026. Epub 2017 Jan 16.


EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.

Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB.

Clin Lung Cancer. 2016 Nov;17(6):483-492. doi: 10.1016/j.cllc.2016.05.016. Epub 2016 Jun 8. Review.


De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.

Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB.

Lung Cancer. 2016 Sep;99:17-22. doi: 10.1016/j.lungcan.2016.06.006. Epub 2016 Jun 14.


Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.

Costa DB, Jorge SE, Moran JP, Freed JA, Zerillo JA, Huberman MS, Kobayashi SS.

J Thorac Oncol. 2016 Jun;11(6):918-23. doi: 10.1016/j.jtho.2016.02.016. Epub 2016 Mar 8.


Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.

Shea M, Huberman MS, Costa DB.

J Thorac Oncol. 2016 Jul;11(7):e81-2. doi: 10.1016/j.jtho.2016.01.017. Epub 2016 Feb 1. No abstract available.


Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB.

Lung Cancer. 2015 Dec;90(3):369-74. doi: 10.1016/j.lungcan.2015.10.028. Epub 2015 Oct 31.


Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice.

Rangachari D, VanderLaan PA, Le X, Folch E, Kent MS, Gangadharan SP, Majid A, Haspel RL, Joseph LJ, Huberman MS, Costa DB.

Cancer Treat Commun. 2015;4:174-181.


Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB.

Clin Lung Cancer. 2015 Sep;16(5):e105-9. doi: 10.1016/j.cllc.2015.03.002. Epub 2015 Mar 25. No abstract available.


De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.

Le X, Desai NV, Majid A, Karp RS, Huberman MS, Rangachari D, Kent MS, Gangadharan SP, Folch E, VanderLaan PA, Costa DB.

Lung Cancer. 2015 Apr;88(1):70-3. doi: 10.1016/j.lungcan.2015.02.003. Epub 2015 Feb 7.


Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB.

Lung Cancer. 2015 Apr;88(1):108-11. doi: 10.1016/j.lungcan.2015.01.020. Epub 2015 Feb 4.


Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.

Vanderlaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON, Costa DB.

Lung Cancer. 2014 Apr;84(1):39-44. doi: 10.1016/j.lungcan.2014.01.013. Epub 2014 Jan 28.


Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.

Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB.

Sci Transl Med. 2013 Dec 18;5(216):216ra177. doi: 10.1126/scitranslmed.3007205. Erratum in: Sci Transl Med. 2014 Feb 26;6(225):225er1.


Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.

Folch E, Yamaguchi N, VanderLaan PA, Kocher ON, Boucher DH, Goldstein MA, Huberman MS, Kent MS, Gangadharan SP, Costa DB, Majid A.

J Thorac Oncol. 2013 Nov;8(11):1438-1444. doi: 10.1097/JTO.0b013e3182a471a9.


Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

Yamaguchi N, Vanderlaan PA, Folch E, Boucher DH, Canepa HM, Kent MS, Gangadharan SP, Majid A, Kocher ON, Goldstein MA, Huberman MS, Costa DB.

Lung Cancer. 2013 Oct;82(1):31-7. doi: 10.1016/j.lungcan.2013.07.013. Epub 2013 Aug 7.


Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB.

J Thorac Oncol. 2013 Jan;8(1):45-51. doi: 10.1097/JTO.0b013e3182781e35.


Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center.

Nguyen KS, Sanford RA, Huberman MS, Goldstein MA, McDonald DM, Farquhar M, Gangadharan SP, Kent MS, Michaud G, Majid A, Berman SM, Aronovitz JA, Nedea EA, Boiselle PM, Cohen DW, Kobayashi S, Costa DB.

J Oncol Pract. 2012 Jan;8(1):57-62. doi: 10.1200/JOP.2011.000274. Epub 2011 Nov 22.


Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer.

Britt GJ, Gaughan EM, Nguyen KS, Warner JL, Goldstein MA, Huberman MS, Costa DB.

J Thorac Dis. 2011 Jun;3(2):141-3. doi: 10.3978/j.issn.2072-1439.2011.03.02.


Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB.

J Thorac Oncol. 2010 Jul;5(7):1048-53. doi: 10.1097/JTO.0b013e3181dd1386.


Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.

Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ.

J Thorac Oncol. 2009 Nov;4(11):1389-96. doi: 10.1097/JTO.0b013e3181b6b84b.


Subdivision of the T1 size descriptor for stage I non-small cell lung cancer has prognostic value: a single institution experience.

Ye C, Masterman JR, Huberman MS, Gangadharan SP, McDonald DC, Kent MS, DeCamp MM.

Chest. 2009 Sep;136(3):710-715. doi: 10.1378/chest.09-0823. Epub 2009 Jun 12. Erratum in: Chest. 2009 Nov;136(5):1446.


Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S.

Clin Cancer Res. 2008 Nov 1;14(21):7060-7. doi: 10.1158/1078-0432.CCR-08-1455.


BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.

PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680.


Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.

Costa DB, Kobayashi S, Tenen DG, Huberman MS.

Lung Cancer. 2007 Oct;58(1):95-103. Epub 2007 Jul 3.


Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.

Clin Cancer Res. 2006 Jul 1;12(13):3908-14.


Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.

Costa DB, Huberman MS.

Diabetes Care. 2006 Jul;29(7):1711. No abstract available.


Uncommon presentations of some common malignancies: Case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancer.

Mayer S, Cypess AM, Kocher ON, Berman SM, Huberman MS, Hartzband PI, Halmos B.

J Clin Oncol. 2005 Feb 20;23(6):1312-4. No abstract available.


Gemcitabine pulmonary toxicity: CT features.

Boiselle PM, Morrin MM, Huberman MS.

J Comput Assist Tomogr. 2000 Nov-Dec;24(6):977-80.


A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.

Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS, Stuart KE.

Cancer. 1998 Jun 15;82(12):2321-5.


Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial.

Sanz-Altamira PM, Spence LD, Huberman MS, Posner MR, Steele G Jr, Perry LJ, Stuart KE.

Dis Colon Rectum. 1997 Jul;40(7):770-5.


Non-Hodgkin's lymphoma of the kidney with inferior vena caval extension.

Eyre RC, Huberman MS, Balogh K.

Urol Int. 1993;51(1):43-5. No abstract available.


A pilot study of sphincter-sparing management of adenocarcinoma of the rectum.

Steele G Jr, Busse P, Huberman MS, LeClair JM, Falchuk ZM, Mayer RJ, Bothe A Jr, Ravikumar TS, Stone M, Jessup JM.

Arch Surg. 1991 Jun;126(6):696-701; discussion 701-2.


Interferon alfa-induced cardiac dysfunction.

Cohen MC, Huberman MS, Nesto RW.

N Engl J Med. 1990 May 17;322(20):1469. No abstract available.


Recombinant alpha 2 interferon-related cardiomyopathy.

Cohen MC, Huberman MS, Nesto RW.

Am J Med. 1988 Oct;85(4):549-51. No abstract available.


Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.

Bern MM, Wallach SR, Arkin CF, Lokich JJ, Huberman MS, Anderson NR, Corkery JC, Paul SD, Phillips DF, Sonneborn HA, et al.

Cancer Treat Rep. 1987 Feb;71(2):201-3.


Non-human primate (baboon) anti-carcinoembryonic antigen antibody infusion in patients with metastatic adenocarcinoma. A phase I study.

Huberman MS, Lokich JJ, Hill T, Kaldany A, Kassis A, Price T, Moore C, Davis S, Kasulis P, Monaco AP, et al.

Cancer Immunol Immunother. 1986;23(2):137-42.


Apparent transmission of human T-cell leukemia virus type III to a heterosexual woman with the acquired immunodeficiency syndrome.

Groopman JE, Sarngadharan MG, Salahuddin SZ, Buxbaum R, Huberman MS, Kinniburgh J, Sliski A, McLane MF, Essex M, Gallo RC.

Ann Intern Med. 1985 Jan;102(1):63-6.


Adriamycin, cyclophosphamide, and etoposide (VP-16-213) in extensive-stage small cell lung cancer.

Matelski HW, Lokich JJ, Huberman MS, Zipoli TE, Paul S, Sonneborn H, Philips D.

Am J Clin Oncol. 1984 Dec;7(6):729-32.


Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma.

Huberman MS.

Semin Oncol. 1983 Jun;10(2):238-48. Review. No abstract available.


Phase II trial of cisplatin in small cell carcinoma of the lung.

Levenson RM Jr, Ihde DC, Huberman MS, Cohen MH, Bunn PA, Minna JD.

Cancer Treat Rep. 1981 Sep-Oct;65(9-10):905-7.


Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination.

Bunn PA Jr, Huberman MS, Whang-Peng J, Schechter GP, Guccion JG, Matthews MJ, Gazdar AF, Dunnick NR, Fischmann AB, Ihde DC, Cohen MH, Fossieck B, Minna JD.

Ann Intern Med. 1980 Aug;93(2):223-30.


Hepatic involvement in the cutaneous T-cell lymphomas: results of percutaneous biopsy and peritoneoscopy.

Huberman MS, Bunn PA Jr, Matthews MJ, Ihde DC, Gazdar AF, Cohen MH, Minna JD.

Cancer. 1980 Apr 1;45(7):1683-8.


Supplemental Content

Loading ...
Support Center